A rise in the global geriatric population, increasing number of patients suffering from Parkinson’s disease (PD) and growing awareness about neurological movement disorders among patients have triggered the growth of the deep brain stimulation devices market. Globally, neurological disorders are one of the major causes of mortality and account for approximately 12% of deaths per annum. Of these, cerebrovascular diseases account for 85% deaths. Parkinson’s disease is the most common neurological disorder after Alzheimer’s disease. Symptoms associated with this disease include tremors, slowness of movement, muscle stiffness and trouble with balance. Drug therapy is the most effective treatment option available to control PD in the initial stages; however, a large number of medicines are required to control the disease during its advanced stages.